

Communication Address:

Solara Active Pharma Sciences Limited
2nd Floor, Admin Block

27, Vandaloor Kelambakkam Road, Keelakottaiyur Village, Melakottaiyur (Post) Chennai – 600 127, India

Tel: +91 44 43446700 Fax: +91 44 47406190

E-mail: investors@solara.co.in

www.solara.co.in

April 28, 2023

The BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001

Scrip Code: 541540

Dear Sir / Madam,

Sub: Statement on Deviation or Variation of funds raised through Preferential Issue of Convertible Warrants for quarter ended December 31, 2022

We refer to your mail dated April 19, 2023, and wish to clarify that pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015 read with SEBI Circular No. *CIRICFD/CMDI116212019* dated December 24,2019, we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated January 31, 2019.

We also wish to inform that funds have been fully utilized for the stated purpose during the year 2020-2021 itself.

This is for your information and records.

Thanking you,

Yours faithfully,

For Solara Active Pharma Sciences Limited

S. Murali Krishna Company Secretary